# IBD malignancy with Hannah Gordon

Page: https://stenobird.com/podcast/ueg-podcast-6404464/ibd-malignancy-with-hannah-gordon
Text version: https://stenobird.com/podcast/ueg-podcast-6404464/ibd-malignancy-with-hannah-gordon.md
Podcast: [UEG Podcast](https://stenobird.com/podcast/ueg-podcast-6404464)
Published: 2026-04-07T22:05:00+00:00
Episode link: https://ueg-talks-podcast.podigee.io/72-new-episode
Audio file: https://audio.podigee-cdn.net/2418826-m-2ecc8ad8c43fdd7b59c0048b31d2a510.mp3?source=feed
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/ueg-podcast-6404464/episodes/ibd-malignancy-with-hannah-gordon
Duration seconds: 2588

## Resource

In this episode, Pradeep Mundre speaks with Hannah Gordon about one of the most challenging areas in inflammatory bowel disease management: balancing effective treatment with cancer risk. As therapeutic options expand, clinicians increasingly face complex scenarios involving patients with prior malignancy in remission or those undergoing active cancer treatment. The discussion examines how cancer risk relates both to IBD itself and to immunosuppressive or biologic therapies. The episode highlights limitations in current evidence, differences across drug classes, and the importance of individualised decision-making. Emphasis is placed on multidisciplinary collaboration, patient communication, and navigating uncertainty in real-world clinical practice.

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/ueg-podcast-6404464/episodes/ibd-malignancy-with-hannah-gordon/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/ueg-podcast-6404464/ibd-malignancy-with-hannah-gordon.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.